Tiziano Barbui
Tiziano Barbui
Fondazione per la Ricerca Ospedale Maggiore di Bergamo
Verified email at
Cited by
Cited by
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
C Harrison, JJ Kiladjian, HK Al-Ali, H Gisslinger, R Waltzman, ...
New England Journal of Medicine 366 (9), 787-798, 2012
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
M Galli, T Barbui, P Comfurius, C Maassen, HC Hemker, RFA Zwaal, ...
The Lancet 335 (8705), 1544-1547, 1990
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi, R Marchioli, J Kutti, H Gisslinger, G Tognoni, C Patrono, ...
New England Journal of Medicine 350 (2), 114-124, 2004
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
M Galli, D Luciani, G Bertolini, T Barbui
Blood, The Journal of the American Society of Hematology 101 (5), 1827-1832, 2003
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
DA Arber, A Orazi, RP Hasserjian, MJ Borowitz, KR Calvo, HM Kvasnicka, ...
Blood, The Journal of the American Society of Hematology 140 (11), 1200-1228, 2022
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis …
A Tefferi, J Thiele, A Orazi, HM Kvasnicka, T Barbui, CA Hanson, G Barosi, ...
Blood, The Journal of the American Society of Hematology 110 (4), 1092-1097, 2007
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
S Cortelazzo, G Finazzi, M Ruggeri, O Vestri, M Galli, F Rodeghiero, ...
New England Journal of Medicine 332 (17), 1132-1137, 1995
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet
T Barbui, G Barosi, G Birgegard, F Cervantes, G Finazzi, M Griesshammer, ...
Journal of clinical oncology 29 (6), 761, 2011
Cardiovascular events and intensity of treatment in polycythemia vera
R Marchioli, G Finazzi, G Specchia, R Cacciola, R Cavazzina, D Cilloni, ...
New England Journal of Medicine 368 (1), 22-33, 2013
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli, G Finazzi, R Landolfi, J Kutti, H Gisslinger, C Patrono, ...
Journal of Clinical Oncology 23 (10), 2224-2232, 2005
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
A Tefferi, P Guglielmelli, DR Larson, C Finke, EA Wassie, L Pieri, ...
Blood, The Journal of the American Society of Hematology 124 (16), 2507-2513, 2014
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A Tefferi, E Rumi, G Finazzi, H Gisslinger, AM Vannucchi, F Rodeghiero, ...
Leukemia 27 (9), 1874-1881, 2013
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA …
MA Sanz, FL Coco, G Martın, G Avvisati, C Rayón, T Barbui, ...
Blood, The Journal of the American Society of Hematology 96 (4), 1247-1253, 2000
Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin
EM Bevers, M Galli, T Barbui, P Comfurius, RFA Zwaal
Thrombosis and haemostasis 66 (12), 629-632, 1991
A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid …
G Finazzi, R Marchioli, V Brancaccio, P Schinco, F Wisloff, J Musial, ...
Journal of Thrombosis and Haemostasis 3 (5), 848-853, 2005
The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia
P Rebulla, G Finazzi, F Marangoni, G Avvisati, L Gugliotta, G Tognoni, ...
New England Journal of Medicine 337 (26), 1870-1875, 1997
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome
JA Coppell, PG Richardson, R Soiffer, PL Martin, NA Kernan, A Chen, ...
Biology of blood and marrow transplantation 16 (2), 157-168, 2010
Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)
T Barbui, G Finazzi, A Carobbio, J Thiele, F Passamonti, E Rumi, ...
Blood, The Journal of the American Society of Hematology 120 (26), 5128-5133, 2012
Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy
F Mandelli, D Diverio, G Avvisati, A Luciano, T Barbui, C Bernasconi, ...
Blood, The Journal of the American Society of Hematology 90 (3), 1014-1021, 1997
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
AM Vannucchi, E Antonioli, P Guglielmelli, A Rambaldi, G Barosi, ...
Blood, The Journal of the American Society of Hematology 110 (3), 840-846, 2007
The system can't perform the operation now. Try again later.
Articles 1–20